Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages

  Catay, Erika ^a   Bravo, Maximiliano ^a   Rosa, Javier ^a,b   Soriano, Enrique R ^a,b  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Fundación Pedro M Catoggio Para el Progreso de la Reumatologia   (Argentina)

Author keywords

Biologic therapy; Drug survival; Monotherapy; Rheumatoid Arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PRESCRIPTION; PREVALENCE; RHEUMATOID ARTHRITIS; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; ELECTRONIC HEALTH RECORD; FOLLOW UP; MIDDLE AGED; TRENDS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84978682034     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-0959-1     Document Type: Article

References (15)

1. Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, Landewe RB, Smolen JS, Sokka T, van der Heijde DM. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):987-94.
2. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34-45.
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.
4. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234-40.
5. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009;36(8):1611-7.
6. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-904.
7. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis. 2008;66(2):77-85.
8. Why do you lie to your doctor? 2004. http://www.medicinenet.com/script/main/art.asp?articlekey=46985. Accessed August 30 2012.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010. 2010;62(9):2569-81.
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2010. 2010;69(9):1580-8.
12. Choquette D, Arundine M, Thomas OC. Large discrepancy between expected and observed ratios of biologic treated rheumatoid arthritis patients also compliant on DMARDs. Ann Rheum Dis. 2011;70(Suppl3):197.
13. Choquette D, Thomas O, Arundine M. Lower than expected levels of DMARD acquisition immediately pre and post biologic initiation in rheumatold arthritis patients. Arthritis Rheum. 2012;64(Suppl 10):1841.
14. Engel-Nitz NM, Ogale S, Kulakodlu M. Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting. [abstract]. Arthritis Rheum. 2012;64(Suppl 10):378.
15. Pappas DA, Reed GW, Saunders K, John A, Shewade A, Greenberg JD, Kremer JM. Rheumatol Ther. 2015 (2):85-96.